does masshealth cover tirzepatide Our Clinical Supervisor, Joseph Zucchi, PA-C, has a new op-ed published on Itemlive regarding the fight to protect access to obesity treatment in Massachusetts. Patients who are finally improving their health may MassHealth Updates: Massachusetts Health Care

Description

Side effects with different GLP-1 drugs may vary from person to person.

While incredibly effective for weight loss, they can also lead to: - Muscle loss from rapid weight reduction - Sagging or loose skin from fat loss in areas like the face, neck, and arms - Hair thinning due to reduced nutrient absorption or lower protein intake - Fatigue and slower recovery from decreased lean mass This is where collagen comes in: to support, stabilise, and strengthen the body during change. Why collagen is a GLP-1 essential Collagen is the structural protein that keeps our skin firm, joints mobile, hair healthy, and muscles supported - as we age, and especially during periods of weight loss, collagen levels drop. A consistent collagen routine can: - Reinforce skin elasticity and prevent loose, sagging skin - Protect lean muscle mass and boost strength during fat loss - Support healthy hair growth and reduce thinning - Improverecovery and energy for active lifestyles Building your GLP-1 collagen routine with Pura At Pura Collagen, our products are formulated for targeted, effective support using hydrolysed collagen peptides for maximum absorption. Morning: Pura Collagen Glow+ For skin, hair, nails, and that healthy glow - Start your day with unflavoured Glow+ in your smoothie, coffee, or fruit juice. - Contains clinically proven VERISOL Bioactive Collagen Peptides to improve skin elasticity and reduce fine lines. - Stimulates hair follicles for fuller, morenourished and healthier hair. - Using 10,000mg ofGlow+ every day can lead to healthier skin, hair and nails in as little as 4 weeks.Rapid weight loss can lead to loose or sagging skin, VERISOLhelps skin adapt to body composition changes by promoting elasticity and firmness

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists medications that are widely prescribed for metabolic disease have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.